ITP
MLYS icon

Iron Triangle Partners’s Mineralys Therapeutics MLYS Stock Holding History

Iron Triangle Partners’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$9.33M Buy
+257,085
New +$10.3M 1.07% 27

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Iron Triangle Partners's MLYS Position: Q4 2025 in Review

Iron Triangle Partners opened a new position in Mineralys Therapeutics (MLYS) in Q4 2025: 257,085 shares worth $9.33M. The stake represents 1.07% of the portfolio and ranks #27 among its holdings.

223 funds tracked by Wall St. Rank hold MLYS as of Q4 2025.

  • Iron Triangle Partners held 257,085 shares of Mineralys Therapeutics worth $9.33M as of Q4 2025.
  • Mineralys Therapeutics was a new Iron Triangle Partners position in Q4 2025.
  • Mineralys Therapeutics made up 1.07% of Iron Triangle Partners's portfolio in Q4 2025, its #27 holding.
  • 223 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q4 2025.

Based on Iron Triangle Partners's 13F filing for Q4 2025, filed 17 Feb 2026.